- Catalent, Inc. has unveiled its new corporate brand, reflecting its renewed focus on customer service and patient-centric innovation.
- The rebrand follows the company’s transition to private ownership under Novo Holdings and the establishment of its new global headquarters in Tampa, Florida.
Catalent, Inc., a global contract development and manufacturing organisation (CDMO), has introduced a new corporate brand designed to reflect its evolving mission of supporting pharmaceutical, biotech and consumer health partners in delivering life-enhancing and life-changing products.
The rebrand highlights Catalent’s commitment to “championing the missions that matter,” aligning its corporate identity with its role in helping customers accelerate therapies and improve global health outcomes.
“At Catalent, we believe that every medicine, therapy and product we help develop, manufacture and deliver exemplifies our commitment to put patients first in everything we do. This new brand and simplified approach speak not only to who we are today, but to the impact we have on global health.”
Alessandro Maselli, President and Chief Executive Officer
The announcement comes as Catalent continues to expand its global operations under Novo Holdings’ ownership, following its transition to private ownership in December 2024. The company’s new headquarters in Tampa, Florida, anchors a network of more than 40 sites worldwide.
Catalent’s scale and expertise support over 1,000 active development programmes annually and production of more than 60 billion doses per year. Over the past decade, the CDMO has contributed to the development and manufacture of products representing half of all U.S. FDA approvals, reinforcing its position as a key partner within the global healthcare ecosystem.
